Univariate | Adjusted modela | |||||
---|---|---|---|---|---|---|
OR | CI (95%) | p value | aOR | CI (95%) | p value | |
Abidjan vs. Ouagadougou | 1.13 | (0.38–3.35) | 0.83 | 0.64 | (0.17–2.41) | 0.51 |
Female vs. Male | 1.14 | (0.40–3.23) | 0.81 | 1.26 | (0.41–3.93) | 0.68 |
Treatment arm | 0.73 | 0.66 | ||||
AZT/ABC + 3TC + LPV/r | Ref. | – | Ref. | – | ||
ABC + 3TC + EFV | 0.83 | (0.29–2.35) | 0.78 | (0.26–2.38) | ||
Mother main caregiver vs. father or other | 1.06 | (0.27–4.14) | 0.94 | – | – | |
Father informed of HIV status of the child | 1.74 | (0.61–4.93) | 0.30 | – | – | |
History of antiretroviral drug exposure | 0.68 | 0.34 | ||||
No previous exposure to any PMTCT or ART | Ref. | – | Ref. | – | ||
Prenatal maternal ART | 0.58 | (0.10–3.51) | 0.32 | (0.04–2.32) | ||
Exposure to PMTCT only | 0.90 | (0.25–3.26) | 0.64 | (0.15–2.68) | ||
Exposure to postnatal maternal ART only | 2.00 | (0.22–18.33) | 1.95 | (0.20–19.24) | ||
PMTCT and postnatal maternal ART | 0.39 | (0.08–1.94) | 0.19 | (0.03–1.21) | ||
Age at randomisation <24 months | 1.63 | (0.53–5.03) | 0.39 | – | – | |
WHO clinical stage at randomisation | 0.04 | 0.01 | ||||
Stage 1, 2, 3 | Ref. | – | Ref. | – | ||
Stage 4 | 0.31 | (0.10–0.95) | 0.18 | (0.05–0.72) |